Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Merck
Accenture
Deloitte
Colorcon
Cipla
Fuji
US Army
Express Scripts

Generated: August 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Heterocyclic compounds for the treatment of neurological and psychological disorders
Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001##
Inventor(s): Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:13/607,066
Patent Claims: 1. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR00950## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, R.sub.5 is selected from Table 1; TABLE-US-00012 TABLE 1 ##STR00951## ##STR00952## ##STR00953## ##STR00954## ##STR00955## ##STR00956## ##STR00957## ##STR00958## ##STR00959## ##STR00960## ##STR00961## ##STR00962## ##STR00963## ##STR00964## ##STR00965## ##STR00966## ##STR00967## ##STR00968## ##STR00969## ##STR00970## ##STR00971## ##STR00972## ##STR00973## ##STR00974## ##STR00975## ##STR00976## ##STR00977## ##STR00978## ##STR00979## ##STR00980## ##STR00981## ##STR00982## ##STR00983## ##STR00984## ##STR00985## ##STR00986## ##STR00987## ##STR00988## ##STR00989## ##STR00990## ##STR00991## ##STR00992## ##STR00993## ##STR00994## ##STR00995## ##STR00996## ##STR00997## ##STR00998## ##STR00999## ##STR01000## ##STR01001## ##STR01002## ##STR01003## ##STR01004## ##STR01005## ##STR01006## ##STR01007## ##STR01008## ##STR01009## ##STR01010## ##STR01011## ##STR01012## ##STR01013## ##STR01014## ##STR01015## ##STR01016## ##STR01017## ##STR01018## ##STR01019## ##STR01020## ##STR01021## ##STR01022## ##STR01023## ##STR01024## ##STR01025## ##STR01026## ##STR01027## ##STR01028## ##STR01029## ##STR01030## ##STR01031## ##STR01032## ##STR01033## ##STR01034## ##STR01035## ##STR01036## ##STR01037## ##STR01038## ##STR01039## ##STR01040## ##STR01041## ##STR01042## ##STR01043## ##STR01044## ##STR01045## ##STR01046## ##STR01047## ##STR01048## ##STR01049## ##STR01050## ##STR01051## ##STR01052## ##STR01053## ##STR01054## ##STR01055## ##STR01056## ##STR01057## ##STR01058## ##STR01059## ##STR01060## ##STR01061##

##STR01062## ##STR01063## ##STR01064## ##STR01065## ##STR01066## ##STR01067## ##STR01068## ##STR01069## ##STR01070## ##STR01071## ##STR01072## ##STR01073## ##STR01074## ##STR01075## ##STR01076## ##STR01077## ##STR01078## ##STR01079## ##STR01080## ##STR01081## ##STR01082## ##STR01083## ##STR01084## ##STR01085## ##STR01086## ##STR01087## ##STR01088## ##STR01089## ##STR01090## ##STR01091## ##STR01092## ##STR01093## ##STR01094## ##STR01095## ##STR01096## ##STR01097## ##STR01098## ##STR01099## ##STR01100## ##STR01101## ##STR01102## ##STR01103## ##STR01104## ##STR01105## ##STR01106## ##STR01107## ##STR01108## ##STR01109## ##STR01110## ##STR01111## ##STR01112## ##STR01113## ##STR01114## ##STR01115## ##STR01116## ##STR01117## ##STR01118## ##STR01119## ##STR01120## ##STR01121## ##STR01122## ##STR01123## ##STR01124## ##STR01125## ##STR01126## ##STR01127## ##STR01128## ##STR01129## ##STR01130## ##STR01131## ##STR01132## ##STR01133## ##STR01134## ##STR01135## ##STR01136## ##STR01137## ##STR01138## ##STR01139## ##STR01140## ##STR01141## ##STR01142## ##STR01143## ##STR01144## ##STR01145## ##STR01146## ##STR01147## ##STR01148## ##STR01149## ##STR01150## ##STR01151## ##STR01152## ##STR01153## ##STR01154## ##STR01155## ##STR01156## ##STR01157## ##STR01158## ##STR01159## ##STR01160## ##STR01161## ##STR01162## ##STR01163## ##STR01164## ##STR01165## ##STR01166## ##STR01167## ##STR01168## ##STR01169## ##STR01170## ##STR01171## ##STR01172## ##STR01173## ##STR01174## ##STR01175## ##STR01176## ##STR01177## ##STR01178## ##STR01179## ##STR01180## ##STR01181## ##STR01182## ##STR01183## ##STR01184## ##STR01185## ##STR01186## ##STR01187##

##STR01188## ##STR01189## ##STR01190## ##STR01191## ##STR01192## ##STR01193## ##STR01194## ##STR01195## ##STR01196## ##STR01197## ##STR01198## ##STR01199## ##STR01200## ##STR01201## ##STR01202## ##STR01203## ##STR01204## ##STR01205## ##STR01206## ##STR01207## ##STR01208## ##STR01209## ##STR01210## ##STR01211## ##STR01212## ##STR01213## ##STR01214## ##STR01215## ##STR01216## ##STR01217## ##STR01218## ##STR01219## ##STR01220## ##STR01221## ##STR01222## ##STR01223## ##STR01224## ##STR01225## ##STR01226## ##STR01227## ##STR01228## ##STR01229## ##STR01230## ##STR01231## ##STR01232## ##STR01233## ##STR01234## ##STR01235## ##STR01236## ##STR01237## ##STR01238## ##STR01239## ##STR01240## ##STR01241## ##STR01242## ##STR01243## ##STR01244## ##STR01245## ##STR01246## ##STR01247## ##STR01248## ##STR01249## ##STR01250## ##STR01251## ##STR01252## ##STR01253## ##STR01254## ##STR01255## ##STR01256## ##STR01257## ##STR01258## ##STR01259## ##STR01260## ##STR01261## ##STR01262## ##STR01263## ##STR01264## ##STR01265## ##STR01266## ##STR01267## ##STR01268## ##STR01269## ##STR01270## ##STR01271## ##STR01272## ##STR01273## ##STR01274## ##STR01275## ##STR01276## ##STR01277## ##STR01278## ##STR01279## ##STR01280## ##STR01281## ##STR01282## ##STR01283## ##STR01284## ##STR01285## ##STR01286## ##STR01287## ##STR01288## ##STR01289## ##STR01290## ##STR01291## ##STR01292## ##STR01293## ##STR01294## ##STR01295## ##STR01296## ##STR01297## ##STR01298## ##STR01299## ##STR01300## ##STR01301## ##STR01302## ##STR01303## ##STR01304## ##STR01305## ##STR01306## ##STR01307## ##STR01308## ##STR01309## ##STR01310## ##STR01311## ##STR01312##

##STR01313## ##STR01314## ##STR01315## ##STR01316## ##STR01317## ##STR01318## ##STR01319## ##STR01320## ##STR01321## ##STR01322## ##STR01323## ##STR01324## ##STR01325## ##STR01326## ##STR01327## ##STR01328## ##STR01329## ##STR01330## ##STR01331## ##STR01332## ##STR01333## ##STR01334## ##STR01335## ##STR01336## ##STR01337## ##STR01338## ##STR01339## ##STR01340## ##STR01341## ##STR01342## ##STR01343## ##STR01344## ##STR01345## ##STR01346## ##STR01347## ##STR01348## ##STR01349## ##STR01350## ##STR01351## ##STR01352## ##STR01353## ##STR01354## ##STR01355## ##STR01356## ##STR01357##

Y and M are the same or different and each is a monovalent cation; or M and Y together is a divalent cation.

2. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound selected from Table A or B or the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof to a patient in need thereof: TABLE-US-00013 TABLE A No Structure 1 ##STR01358## 2 ##STR01359## 3 ##STR01360## 4 ##STR01361## 5 ##STR01362## 6 ##STR01363## 7 ##STR01364## 8 ##STR01365## 9 ##STR01366## 10 ##STR01367## 11 ##STR01368## 12 ##STR01369## 13 ##STR01370## 14 ##STR01371## 15 ##STR01372## 16 ##STR01373## 17 ##STR01374## 18 ##STR01375## 19 ##STR01376## 20 ##STR01377## 21 ##STR01378## 22 ##STR01379## 23 ##STR01380## 24 ##STR01381## 25 ##STR01382## 26 ##STR01383## 27 ##STR01384## 28 ##STR01385## 29 ##STR01386## 30 ##STR01387## 31 ##STR01388## 32 ##STR01389## 33 ##STR01390## 34 ##STR01391## 35 ##STR01392## 36 ##STR01393## 37 ##STR01394## 38 ##STR01395## 39 ##STR01396## 40 ##STR01397## 41 ##STR01398## 42 ##STR01399## 43 ##STR01400## 44 ##STR01401## 45 ##STR01402## 46 ##STR01403## 47 ##STR01404## 48 ##STR01405## 49 ##STR01406## 50 ##STR01407## 51 ##STR01408## 52 ##STR01409## 53 ##STR01410## 54 ##STR01411## 55 ##STR01412## 56 ##STR01413## 57 ##STR01414## 58 ##STR01415## 59 ##STR01416## 60 ##STR01417## 61 ##STR01418## 62 ##STR01419## 63 ##STR01420## 64 ##STR01421## 65 ##STR01422## 66 ##STR01423## 67 ##STR01424## 68 ##STR01425## 69 ##STR01426## 70 ##STR01427## 71 ##STR01428## 72 ##STR01429## 73 ##STR01430## 74 ##STR01431## 75 ##STR01432## 76 ##STR01433## 77 ##STR01434## 78 ##STR01435## 79 ##STR01436## 80 ##STR01437## 81 ##STR01438## 82 ##STR01439## 83 ##STR01440## 84 ##STR01441## 85 ##STR01442## 86 ##STR01443## 87 ##STR01444## 88 ##STR01445## 89 ##STR01446## 90 ##STR01447## 91 ##STR01448## 92 ##STR01449## 93 ##STR01450## 94 ##STR01451## 95 ##STR01452## 96 ##STR01453## 97 ##STR01454## 98 ##STR01455## 99 ##STR01456## 100 ##STR01457## 101 ##STR01458## 102 ##STR01459## 103 ##STR01460## 104 ##STR01461## 105 ##STR01462## 106 ##STR01463## 107 ##STR01464## 108 ##STR01465## 109 ##STR01466## 110 ##STR01467## 111 ##STR01468## 112 ##STR01469## 113 ##STR01470## 114 ##STR01471## 115 ##STR01472## 116 ##STR01473## 117 ##STR01474## 118 ##STR01475##

TABLE-US-00014 TABLE B No Structure 150 ##STR01476## 151 ##STR01477## 152 ##STR01478## 153 ##STR01479## 154 ##STR01480## 155 ##STR01481## 156 ##STR01482## 157 ##STR01483## 158 ##STR01484## 159 ##STR01485## 160 ##STR01486## 161 ##STR01487## 162 ##STR01488## 163 ##STR01489## 164 ##STR01490## 165 ##STR01491## 166 ##STR01492## 167 ##STR01493## 168 ##STR01494## 169 ##STR01495## 170 ##STR01496## 171 ##STR01497## 172 ##STR01498## 173 ##STR01499## 174 ##STR01500## 175 ##STR01501## 176 ##STR01502## 177 ##STR01503## 178 ##STR01504## 179 ##STR01505## 180 ##STR01506## 181 ##STR01507## 182 ##STR01508## 183 ##STR01509## 184 ##STR01510## 185 ##STR01511## 186 ##STR01512## 187 ##STR01513## 188 ##STR01514## 189 ##STR01515## 190 ##STR01516## 191 ##STR01517## 192 ##STR01518## 193 ##STR01519## 194 ##STR01520## 195 ##STR01521## 196 ##STR01522## 197 ##STR01523## 198 ##STR01524## 199 ##STR01525## 200 ##STR01526## 201 ##STR01527## 202 ##STR01528## 203 ##STR01529## 204 ##STR01530## 205 ##STR01531## 206 ##STR01532## 207 ##STR01533## 208 ##STR01534## 209 ##STR01535## 210 ##STR01536## 211 ##STR01537## 212 ##STR01538## 213 ##STR01539## 214 ##STR01540## 215 ##STR01541## 216 ##STR01542## 217 ##STR01543## 218 ##STR01544## 219 ##STR01545## 220 ##STR01546## 221 ##STR01547## 222 ##STR01548## 223 ##STR01549## 224 ##STR01550## 225 ##STR01551## 226 ##STR01552## 227 ##STR01553## 228 ##STR01554## 229 ##STR01555## 230 ##STR01556## 231 ##STR01557## 232 ##STR01558## 233 ##STR01559## 234 ##STR01560## 235 ##STR01561## 236 ##STR01562## 237 ##STR01563## 238 ##STR01564## 239 ##STR01565## 240 ##STR01566## 241 ##STR01567## 242 ##STR01568## 243 ##STR01569## 244 ##STR01570## 245 ##STR01571## 246 ##STR01572## 247 ##STR01573## 248 ##STR01574## 249 ##STR01575## 250 ##STR01576## 251 ##STR01577## 252 ##STR01578## 253 ##STR01579## 254 ##STR01580## 255 ##STR01581## 256 ##STR01582## 257 ##STR01583## 258 ##STR01584## 259 ##STR01585## 260 ##STR01586## 261 ##STR01587## 262 ##STR01588## 263 ##STR01589## 264 ##STR01590## 265 ##STR01591## 266 ##STR01592## 267 ##STR01593##

3. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01594## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from: ##STR01595## wherein R.sub.105, R.sub.106 and R.sub.107 are independently selected from hydrogen, halogen, optionally substituted C.sub.1-C.sub.24 alkyl, optionally substituted C.sub.2-C.sub.24 alkenyl, optionally substituted C.sub.2-C.sub.24 alkynyl, optionally substituted C.sub.3-C.sub.24 cycloalkyl, optionally substituted C.sub.1-C.sub.24 alkoxy, optionally substituted C.sub.1-C.sub.24 alkylamino and optionally substituted C.sub.1-C.sub.24 aryl; and, Y and M are the same or different and each is a monovalent cation; or M and Y together is a divalent cation.

4. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01596## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is independently selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from: ##STR01597## ##STR01598## ##STR01599## wherein, each x and y is independently an integer between 0 and 30, and wherein R.sub.105, R.sub.106 and R.sub.107 are independently selected from hydrogen, halogen, optionally substituted C.sub.1-C.sub.24 alkyl, optionally substituted C.sub.2-C.sub.24 alkenyl, optionally substituted C.sub.2-C.sub.24 alkynyl, optionally substituted C.sub.3-C.sub.24 cycloalkyl, optionally substituted C.sub.1-C.sub.24 alkoxy, optionally substituted C.sub.1-C.sub.24 alkylamino and optionally substituted C.sub.1-C.sub.24 aryl; and, Y and M are the same or different and each is a monovalent cation; or M and Y together is a divalent cation.

5. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01600## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from: ##STR01601##

6. A method of treating schizophrenia, mania, anxiety or bipolar disease by administering a compound selected from Compounds 5-10 or a pharmaceutically acceptable salt thereof to a patient in need thereof: ##STR01602##

7. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01603## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from Table 2: TABLE-US-00015 TABLE 2 ##STR01604## ##STR01605## ##STR01606## ##STR01607## ##STR01608## ##STR01609## ##STR01610## ##STR01611## ##STR01612## ##STR01613## ##STR01614## ##STR01615## ##STR01616## ##STR01617## ##STR01618## ##STR01619## ##STR01620## ##STR01621## ##STR01622## ##STR01623## ##STR01624## ##STR01625## ##STR01626## ##STR01627## ##STR01628## ##STR01629## ##STR01630## ##STR01631## ##STR01632## ##STR01633## ##STR01634## ##STR01635## ##STR01636## ##STR01637## ##STR01638## ##STR01639## ##STR01640## ##STR01641## ##STR01642## ##STR01643## ##STR01644## ##STR01645## ##STR01646## ##STR01647## ##STR01648## ##STR01649## ##STR01650## ##STR01651## ##STR01652## ##STR01653## ##STR01654##

8. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01655## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from Table 3: TABLE-US-00016 TABLE 3 ##STR01656## ##STR01657## ##STR01658## ##STR01659## ##STR01660## ##STR01661## ##STR01662## ##STR01663## ##STR01664## ##STR01665## ##STR01666## ##STR01667## ##STR01668## ##STR01669## ##STR01670## ##STR01671## ##STR01672## ##STR01673## ##STR01674## ##STR01675##

9. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01676## wherein represents a single or double bond; A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.1 is selected from absent, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.5 is selected from Table 4: TABLE-US-00017 TABLE 4 ##STR01677## ##STR01678## ##STR01679## ##STR01680## ##STR01681## ##STR01682## ##STR01683## ##STR01684## ##STR01685## ##STR01686## ##STR01687## ##STR01688## ##STR01689## ##STR01690## ##STR01691## ##STR01692## ##STR01693## ##STR01694## ##STR01695## ##STR01696## ##STR01697## ##STR01698## ##STR01699## ##STR01700## ##STR01701## ##STR01702## ##STR01703## ##STR01704## ##STR01705## ##STR01706## ##STR01707## ##STR01708## ##STR01709## ##STR01710## ##STR01711## ##STR01712## ##STR01713## ##STR01714## ##STR01715## ##STR01716## ##STR01717## ##STR01718## ##STR01719## ##STR01720##

10. A method of treating schizophrenia, mania, anxiety or bipolar disease by administering a compound of Formula V or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01721## or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof: wherein represents a single or double bond; R.sub.5 is selected from --CH(R.sub.10)--OR.sub.20, --CH(R.sub.10)--OC(O)OR.sub.20, --CH(R.sub.10)--OC(O)R.sub.20, --CH(R.sub.10)--OC(O)NR.sub.20R.sub.21, --(CH(R.sub.10))--OPO.sub.3MY, --(CH(R.sub.10))--OP(O)(OR.sub.20)(OR.sub.21), --[CH(R.sub.10)O].sub.z--R.sub.20, --[CH(R.sub.10)O]--C(O)OR.sub.20, --[CH(R.sub.10)O].sub.z--C(O)R.sub.20, --[CH(R.sub.10)O].sub.z--C(O)NR.sub.20R.sub.21, --[CH(R.sub.10)O]z-OPO.sub.3MY, --[CH(R.sub.10)O].sub.z--P(O).sub.2(OR.sub.20)M and --[CH(R.sub.10)O].sub.z--P(O)(OR.sub.20)(OR.sub.21); wherein z is 1, 2, 3, 4, 5, 6, or 7; each R.sub.20 and R.sub.21 is independently selected from hydrogen, aliphatic, substituted aliphatic, aryl or substituted aryl; Y and M are the same or different and each is a monovalent cation; or M and Y together is a divalent cation; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; and, w is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

11. A method of treating schizophrenia, mania, anxiety or bipolar disease by administering a compound of formula: ##STR01722## or a pharmaceutically acceptable salt thereof to a patient in need thereof.

12. A method of treating schizophrenia, mania, anxiety or bipolar disease by administering a compound of formula: ##STR01723## or a pharmaceutically acceptable salt thereof to a patient in need thereof.

13. A method of treating schizophrenia, mania, anxiety or bipolar disease by administering a compound of formula: ##STR01724## or a pharmaceutically acceptable salt thereof to a patient in need thereof.

14. A method of treating schizophrenia, mania, bipolar disorder, anxiety or depression by administering a compound of Formula III or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates to a patient in need thereof: ##STR01725## wherein represents a single or double bond; wherein A is selected from absent, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl; R.sub.2 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl. R.sub.3 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.4 is selected from absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; R.sub.5 is selected from --CH(R.sub.10)--OR.sub.20, --CH(R.sub.10)--OC(O)OR.sub.20, --CH(R.sub.10)--OC(O)R.sub.20, --CH(R.sub.10)--OC(O)NR.sub.20R.sub.21, --(CH(R.sub.10))--OPO.sub.3MY, --(CH(R.sub.10))--OP(O)(OR.sub.20)(OR.sub.21), --[CH(R.sub.10)O].sub.z--R.sub.20, --[CH(R.sub.10)O].sub.z--C(O)OR.sub.20, --[CH(R.sub.10)O].sub.z--C(O)R.sub.20, --[CH(R.sub.10)O].sub.z--C(O)NR.sub.20R.sub.21, --[CH(R.sub.10)O]z-OPO.sub.3MY, --[CH(R.sub.10)O].sub.z--P(O).sub.2(OR.sub.20)M and --[CH(R.sub.10)O].sub.z--P(O)(OR.sub.20)(OR.sub.21); wherein z is 1, 2, 3, 4, 5, 6, or 7; each R.sub.20 and R.sub.71 is independently selected from hydrogen, aliphatic, substituted aliphatic, aryl or substituted aryl; Y and M are the same or different and each is a monovalent cation; or M and Y together is a divalent cation; R.sub.10 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; R.sub.11 is absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; D is selected from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--, --C(O)--; m and q are independently selected from 0, 1, and 2; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and, wherein R.sub.1 is selected from: ##STR01726## ##STR01727## wherein R.sub.100 R.sub.101, and R.sub.103 are independently selected from hydrogen, halogen, optionally substituted C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.2-C.sub.8 alkenyl, optionally substituted C.sub.2-C.sub.8 alkynyl, optionally substituted C.sub.3-C.sub.8 cycloalkyl, optionally substituted C.sub.1-C.sub.8 alkoxy, optionally substituted C.sub.1-C.sub.8 alkylamino and optionally substituted C.sub.1-C.sub.8 aryl.

15. The method according to claim 14, wherein R.sub.1 is selected from: ##STR01728##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Merck
QuintilesIMS
Julphar
Chubb
Express Scripts
Deloitte
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot